Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Polynovo ( (AU:PNV) ) has issued an announcement.
PolyNovo Limited reported a significant increase in its financial performance for FY25, with group sales reaching A$118.6 million, marking a 28.9% increase from the previous year. The company achieved a net profit after tax of A$13.2 million, a 151.2% rise from the prior year. Key achievements include the successful U.S. launch of NovoSorb MTX, strong sales growth in various international markets, and the registration of NovoSorb products in multiple countries. These developments enhance PolyNovo’s market positioning and indicate a positive trajectory for future growth.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo Limited operates in the medical technology industry, focusing on the development and commercialization of innovative wound care solutions. Its primary products include the NovoSorb range, which is used for dermal regeneration and surgical applications. The company has a strong market presence in the U.S. and is expanding its reach globally.
YTD Price Performance: -46.08%
Average Trading Volume: 2,086,632
Technical Sentiment Signal: Sell
Current Market Cap: A$759.9M
Find detailed analytics on PNV stock on TipRanks’ Stock Analysis page.